Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
5.74
-0.02 (-0.35%)
At close: Sep 26, 2025, 4:00 PM EDT
5.84
+0.10 (1.74%)
After-hours: Sep 26, 2025, 7:48 PM EDT
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 33 employees as of December 31, 2024. The number of employees increased by 4 or 13.79% compared to the previous year.
Employees
33
Change (1Y)
4
Growth (1Y)
13.79%
Revenue / Employee
n/a
Profits / Employee
-$890,344
Market Cap
279.00M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EPRX News
- 3 days ago - Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option - GlobeNewsWire
- 5 days ago - Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares - GlobeNewsWire
- 5 days ago - Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares - GlobeNewsWire
- 6 weeks ago - Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis - GlobeNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - GlobeNewsWire
- 5 months ago - Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 - GlobeNewsWire